Literature DB >> 18448270

Memory function before and after whole brain radiotherapy in patients with and without brain metastases.

Grit Welzel1, Katharina Fleckenstein, Jörg Schaefer, Brigitte Hermann, Uta Kraus-Tiefenbacher, Sabine K Mai, Frederik Wenz.   

Abstract

PURPOSE: To prospectively compare the effect of prophylactic and therapeutic whole brain radiotherapy (WBRT) on memory function in patients with and without brain metastases. METHODS AND MATERIALS: Adult patients with and without brain metastases (n = 44) were prospectively evaluated with serial cognitive testing, before RT (T0), after starting RT (T1), at the end of RT (T2), and 6-8 weeks (T3) after RT completion. Data were obtained from small-cell lung cancer patients treated with prophylactic cranial irradiation, patients with brain metastases treated with therapeutic cranial irradiation (TCI), and breast cancer patients treated with RT to the breast.
RESULTS: Before therapy, prophylactic cranial irradiation patients performed worse than TCI patients or than controls on most test scores. During and after WBRT, verbal memory function was influenced by pretreatment cognitive status (p < 0.001) and to a lesser extent by WBRT. Acute (T1) radiation effects on verbal memory function were only observed in TCI patients (p = 0.031). Subacute (T3) radiation effects on verbal memory function were observed in both TCI and prophylactic cranial irradiation patients (p = 0.006). These effects were more pronounced in patients with above-average performance at baseline. Visual memory and attention were not influenced by WBRT.
CONCLUSIONS: The results of our study have shown that WBRT causes cognitive dysfunction immediately after the beginning of RT in patients with brain metastases only. At 6-8 weeks after the end of WBRT, cognitive dysfunction was seen in patients with and without brain metastases. Because cognitive dysfunction after WBRT is restricted to verbal memory, patients should not avoid WBRT because of a fear of neurocognitive side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448270     DOI: 10.1016/j.ijrobp.2008.03.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  80 in total

1.  Stereotactic radiation therapy for progressive residual pilocytic astrocytomas.

Authors:  Karlo J Lizarraga; Alessandra Gorgulho; Steve P Lee; Glenn Rauscher; Michael T Selch; Antonio A F DeSalles
Journal:  J Neurooncol       Date:  2012-05-27       Impact factor: 4.130

2.  Shenqi fuzheng injection attenuates irradiation-induced brain injury in mice via inhibition of the NF-κB signaling pathway and microglial activation.

Authors:  Jian Zhang; Fan Tong; Qian Cai; Ling-juan Chen; Ji-hua Dong; Gang Wu; Xiao-rong Dong
Journal:  Acta Pharmacol Sin       Date:  2015-11       Impact factor: 6.150

3.  [In Process Citation].

Authors: 
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-11       Impact factor: 0.840

4.  Effective method to reduce the normal brain dose in single-isocenter hypofractionated stereotactic radiotherapy for multiple brain metastases.

Authors:  Jialu Lai; Jia Liu; Jianling Zhao; An Li; Shoupeng Liu; Zhonghua Deng; Qiaoyue Tan; Haitao Wang; Yuming Jia; Kaijian Lei; Lin Zhou
Journal:  Strahlenther Onkol       Date:  2021-03-16       Impact factor: 3.621

5.  Cerebral microvascular rarefaction induced by whole brain radiation is reversible by systemic hypoxia in mice.

Authors:  Junie P Warrington; Anna Csiszar; Daniel A Johnson; Terence S Herman; Salahuddin Ahmad; Yong Woo Lee; William E Sonntag
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-24       Impact factor: 4.733

Review 6.  Why avoid the hippocampus? A comprehensive review.

Authors:  Vinai Gondi; Wolfgang A Tomé; Minesh P Mehta
Journal:  Radiother Oncol       Date:  2010-10-20       Impact factor: 6.280

7.  [Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. The radiation-oncological view].

Authors:  G Welzel; F Wenz
Journal:  Strahlenther Onkol       Date:  2012-06       Impact factor: 3.621

8.  Outcome and prognostic factors in single brain metastases from small-cell lung cancer.

Authors:  Denise Bernhardt; Sebastian Adeberg; Farastuk Bozorgmehr; Nils Opfermann; Juliane Hörner-Rieber; Laila König; Jutta Kappes; Michael Thomas; Andreas Unterberg; Felix Herth; Claus Peter Heußel; Arne Warth; Jürgen Debus; Martin Steins; Stefan Rieken
Journal:  Strahlenther Onkol       Date:  2017-10-30       Impact factor: 3.621

Review 9.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

10.  The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.

Authors:  Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-04-28       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.